TSW
SUPN icon

Thompson Siegel & Walmsley’s Supernus Pharmaceuticals SUPN Stock Holding History

Thompson Siegel & Walmsley’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-42
Closed -$1K – 891
2017
Q1 		$1K Hold
42
– – ﹤0.01% 822
2016
Q4 		$1K Buy
+42
New +$938 ﹤0.01% 838

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
RCAMU
Rothschild & Co Asset Management US Stamford, Connecticut $6.58B AUM 4.5% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.58B AUM 51% 1-Year Est. Return

Thompson Siegel & Walmsley's SUPN Position: Q2 2017 in Review

Thompson Siegel & Walmsley sold out of Supernus Pharmaceuticals (SUPN) in Q2 2017, closing a stake of 42 shares — an estimated $1K sold.

Thompson Siegel & Walmsley first reported a position in SUPN in Q4 2016 and held it in 2 quarters. The position peaked at $1K in Q1 2017. 266 funds tracked by Wall St. Rank hold SUPN as of Q2 2017.

  • Thompson Siegel & Walmsley reported no remaining Supernus Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Thompson Siegel & Walmsley sold 42 Supernus Pharmaceuticals shares in Q2 2017, an estimated $1K.
  • Thompson Siegel & Walmsley first reported a position in Supernus Pharmaceuticals in Q4 2016 and held it in 2 quarters.
  • Thompson Siegel & Walmsley's Supernus Pharmaceuticals position peaked at $1K in Q1 2017.
  • 266 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2017.

Based on Thompson Siegel & Walmsley's 13F filing for Q2 2017, filed 9 Aug 2017.